• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Class 2 Device Recall MicroScan LabPro V5.0

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
 Class 2 Device Recall MicroScan LabPro V5.0see related information
Date Initiated by FirmOctober 05, 2026
Date PostedNovember 17, 2026
Recall Status1 Open3, Classified
Recall NumberZ-0472-2027
Recall Event ID 100090
Product Classification Medical device data system - Product Code OUG
ProductMicroScan LabPro V5.0 Maintenance Update 1 W/ Panel Update 09 DVD Kit (MR): Catalog Number C82964 LabPro V5.0 Maintenance Update 1 W/ Panel Update 09 DVD Kit (MR) Catalog C90384 LabPro V5.0 Maintenance Update 1 w/ Panel Update 09 (MR), Electronic
Code Information Catalog Number C82964 LabPro V5.0 Maintenance Update 1 W/ Panel Update 09 DVD Kit (MR) Catalog C90384 LabPro V5.0 Maintenance Update 1 w/ Panel Update 09 (MR), Electronic
FEI Number 2050012
Recalling Firm/
Manufacturer
Beckman Coulter Inc.
250 S Kraemer Blvd
Brea CA 92821-6232
For Additional Information ContactKurtis Montegna
530-893-4333
Manufacturer Reason
for Recall
Software defects that may affect antimicrobial susceptibility testing.
FDA Determined
Cause 2
Software design
ActionOn 10/5/2026, an "URGENT FIELD SAFETY NOTICE" Letter was sent via postal mail and/or email informing customers that, Beckman Coulter has identified software implementation errors in the products listed above which may affect antimicrobial susceptibility testing. Incorrect algorithms were implemented for Gram Positive Daptomycin, Gram Positive Clindamycin and Gram Positive Vancomycin, which may result in false susceptible or false resistant/ elevated MIC results when using instrument reads. Customers are instructed to: 1. Manually verify results as shown below - Affected Assays, Instrument Reads, and Panel Part Numbers. 2. Continue routine quality control procedures, review flagged or unusual panel results and follow laboratory verification practices prior to reporting results. 3. Share the content of this letter with laboratory and/or medical director regarding the need to review previous patient test results. 4. Posting this letter on or near the affected analyzers.
Quantity in Commerce1199
DistributionInternational distribution in the countries of Argentina, Bahrain, Belgium, Botswana, Brazil, Chile, Colombia, Czechia, Ecuador, France, Germany, Ghana, Greece, Guadeloupe, Hong Kong, India, Italy, Jordan, Kazakhstan, Korea Republic of, Kuwait, Martinique, Morocco, Namibia, Paraguay, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, South Africa, Spain, Switzerland, Thailand, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland, Uruguay, Vietnam.
Total Product Life CycleTPLC Device Report

1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
-
-